2004.8-2006.5 中國科學(xué)院上海有機(jī)化學(xué)研究所，生命有機(jī)國家重點(diǎn)實(shí)驗(yàn)室，計(jì)算生物學(xué)，博士后
2006.6-2011.8 美國文安諾研究所（Van Andel Institute），結(jié)構(gòu)生物學(xué)與藥物發(fā)現(xiàn)中心，計(jì)算與結(jié)構(gòu)生物學(xué)，博士后
2011.9-今??????? 中國科學(xué)院廣州生物醫(yī)藥與健康研究院，研究員，課題組長，博士生導(dǎo)師，化學(xué)生物學(xué)與藥物研究中心主任（2021年起）
2016年-今????? 廣東省生物醫(yī)藥計(jì)算重點(diǎn)實(shí)驗(yàn)室，副主任
綜合運(yùn)用藥物分子設(shè)計(jì)、藥物化學(xué)、結(jié)構(gòu)生物學(xué)、計(jì)算生物學(xué)和藥理學(xué)等多學(xué)科交叉策略，開展針對惡性腫瘤等疾病的新藥物靶標(biāo)發(fā)現(xiàn)與確證、藥物作用機(jī)制研究以及創(chuàng)新藥物開發(fā)研究。
2013- 廣東省高性能計(jì)算學(xué)會(huì)，副理事長
2015- 廣東省藥學(xué)會(huì)藥物化學(xué)專業(yè)委員會(huì)委員
2018年 廣東省自然科學(xué)獎(jiǎng)二等獎(jiǎng) （第一完成人）
2016年 美國前列腺癌基金會(huì)挑戰(zhàn)獎(jiǎng)
累計(jì)在Nat Med、Cell Res、Nat Struct Mol Biol、J Med Chem等雜志上發(fā)表SCI論文80余篇，申請專利22項(xiàng)，獲授權(quán)8項(xiàng)。
1. Qiu Li#, Benqiang Yao#, Shiting Zhao, Zhou Lu, Yan Zhang, Qiuping Xiang, Xishan Wu, Haonan Yu, Cheng Zhang, Junhua Li, Xiaoxi Zhuang, Donghai Wu, Yong Li, Yong Xu. Discovery of a Highly Selective and H435R Sensitive Thyroid Hormone Receptor?? Agonist.
J Med Chem. 2022 May 4. Doi: 10.1021/acs.jmedchem.2c00144.
2. Li J#, Zhang C#, Xu H, Wang C, Dong R, Shen H, Zhuang X, Chen X, Li Q, Lu J, Zhang M, Wu X, Loomes KM, Zhou Y, Zhang Y, Liu J, Xu Y. Structure- Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.
J Med Chem.2022,?65,?5760-5799.
3. Xiang Q, Wang C, Wu T, Zhang C, Hu Q, Luo G, Hu J, Zhuang X, Zou L, Shen H, Wu X, Zhang Y, Kong X, Liu J, Xu Y. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
J Med Chem. 2022, 65, 785-810
4. Wu X#, Shen H#, Zhang Y#, Wang C, Li Q, Zhang C, Zhuang X, Li C, Shi Y, Xing Y, Xiang Q, Wu D, Liu J, Xu Y*. Discovery and characterization of benzimidazole derivative XY123 as a selective, and orally available ROR??inverse agonist.
J Med Chem. 2021, 64, 8775-8797
5. Wu X, Zhang Y, Xu Y*. Discovery of the First Low Nanomolar Liver Receptor Homolog-1 (LRH-1) Agonist.
? J Med Chem. 2019, 62, 11019-11021
6. Zhang Y#, Wu X#, Xue X#, Li C, Wang J, Wang R, Zhang C, Wang C, Shi Y, Zou L, Li Q, Huang Z, Hao X, Loomes K, Wu D, Chen HW, Xu J, Xu Y*. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable ROR??Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
? J Med Chem. 2019, 62, 4716-4730
7. Zhang M#, Zhang Y#, Song M#, Xue X, Wang J, Wang C, Zhang C, Li C, Xiang Q, Wu X, Wu C, Dong B, Xue We, Zhou Y, Chen H, Wu D, Ding K, Xu Y*. Structure-Based Discovery and Optimization of Benzo[d]isoxazole Derivatives as Potent and Selective BET Inhibitors as Potential Treatment for Castration-Resistant Prostate Cancer (CRPC).
???? J Med Chem, 2018. 61, 3037-3058
8. Wang, J.; Zou, J.X.; Xue, X.; Cai, D.; Zhang, Y.; Duan, Z.; Xiang, Q.; Yang, J.C.; Louie, M.C.; Borowsky, A.D.; Gao, A.C,; Evans, C.P.; Lam, K.S.; Xu, J.; Kung, H.J.; Evans, R.M.; Xu, Y.*; Chen, H.W.*; ROR-??drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.
?? Nat Med, 2016, 22: 488-496.
9. Xue, X#.; Zhang, Y#.; Liu, Z#.; Song, M.; Xing, Y.; Xiang, Q.; Wang, Z.; Tu, Z.; Zhou, Y.; Ding, K.; Xu Y*. Discovery of benzo[cd]indol-2(1H)-ones as potent and specific BET bromodomain inhibitors: structure-based virtual screening, optimization, and biological evaluation.
?? J Med Chem, 2016, 59, 1565-1579
10.Cao, M.; Liu, X.; Zhang, Y.; Xue, X.; Zhou, X. E.; Melcher, K.; Gao, P.; Wang, F.; Zeng, L.; Zhao, Y.; Zhao, Y.; Deng, P.; Zhong, D.; Zhu, J. K.*; Xu, H. E.*; Xu, Y*. An ABA-mimicking ligand that reduces water loss and promotes drought resistance in plants. （共同通訊）
?? Cell Res, 2013, 23, 1043-1054.
